Trusted Resources: Education
Scientific literature and patient education texts
A Caregiver’s Guide to Zolgensma
source: Novartis Gene Therapies, Inc
year: 2021
summary/abstract:Indication
ZOLGENSMA® (onasemnogene abeparvovec-xioi) is a prescription gene therapy used to treat children less than 2 years old with spinal muscular atrophy (SMA). ZOLGENSMA is given as a one-time infusion into a vein. ZOLGENSMA was not evaluated in patients with advanced SMA.
Important Safety Information
ZOLGENSMA can increase liver enzyme levels and cause acute serious liver injury or acute liver failure. Patients will receive an oral corticosteroid before and after infusion with ZOLGENSMA and will undergo regular blood tests to monitor liver function. Contact the patient’s doctor immediately if the patient’s skin and/or whites of the eyes appear yellowish, if the patient misses a dose of corticosteroid or vomits it up, or if the patient experiences a decrease in alertness.
read more
Related Content
-
Spinal Muscular Atrophy 2019: SMA Pathophysiology, Diagnosis and Clinical Presentationshttps://www.youtube.com/watch?v=cUuWue8M...
-
Gene Replacement Therapy With Onasemnogene Abeparvovec in Children With Spinal Muscular Atrophy Aged 24 Months or Yo...Given the novelty of gene replacement th...
-
Combination Therapy With Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type ISpinal muscular atrophy (SMA) is a neuro...
-
SMA Gene Replacement Therapyhttps://www.youtube.com/watch?v=vHbJs8bm...
-
Spinal Muscular Atrophy Fact SheetWhat is spinal muscular atrophy?Spinal m...
-
Coverage of Genetic Therapies for Spinal Muscular Atrophy Across Fee-for-Service Medicaid ProgramsBackground: Genetic therapies are a prom...
-
New Treatment Can Help Fresno Infant With Rare Genetic DisorderA Fresno family is holding onto hope aft...